We compared the in vitro efficacies of two-, three-, and four-drug combinations (1, 3, 9, 30, 33, 37, 38) . These include (i) alternating/sequential therapy in which single drugs are taken individually on an alternating schedule, (ii) combined administration of two or more agents, and (iii) combination, alternating/sequential regimens in which two or more drugs are alternated with two or more different agents.
Monotherapy of human immunodeficiency virus type 1 (HIV-1) infection has met with only partial success. HIV-1 isolates with reduced susceptibility to single agents following monotherapy of HIV-1 infection in vivo (24, 27, 34) and in vitro (23) have now been reported. Recently, greater emphasis has been placed on the development and investigation of combination regimens for the treatment of HIV-1 infection (25) . Several therapeutic strategies are being considered in an attempt to optimize efficacy and minimize toxicity of multidrug combination regimens (1, 3, 9, 30, 33, 37, 38) . These include (i) alternating/sequential therapy in which single drugs are taken individually on an alternating schedule, (ii) combined administration of two or more agents, and (iii) combination, alternating/sequential regimens in which two or more drugs are alternated with two or more different agents.
In the treatment of HIV-1 infection, combination chemotherapy offers several potential advantages over monotherapy: (i) an additive or synergistic effect of two or more combined agents; (ii) reduced dosages, allowing decreased toxicity without sacrificing efficacy; (iii) the use of two or more agents with nonoverlapping. toxicities, resulting in improved efficacy without compounding the toxicities of any of the agents used individually; (iv) delay of the emergence of drug-resistant mutants of HIV-1 or reduction in their numbers if they are already present; (v) targeting of different viral reservoirs by individual agents; and (vi) targeting of cells at different stages of activation (15, 25, 29, 32) .
We evaluated several two-, three-, and four-drug regimens for their abilities to block spread of HIV-1 infection through peripheral blood mononuclear cell (PBMC) cultures and compared the results with those obtained with single-drug regimens. Agents acting at the same as well as at different sites in the HIV-1 replicative cycle were used. Continuous combination regimens were compared with alternating combination regimens.
MATERIALS AND METHODS
.Cells. PBMCs from HIV-1-seronegative donors were obtained by Ficoll-Hypaque density gradient centrifugation of heparinized venous blood. PBMCs were treated with phytohemagglutinin (PHA-P, 2 p,g/ml; Difco Laboratories, Detroit, Mich.), propagated in R-20 medium (RPMI 1640 medium supplemented with 20% heat-inactivated fetal bovine serum [Sigma Chemical, St. Louis, Mo.], 50 U of penicillin per ml, 50 pLg of streptomycin per ml, 2 mM L-glutamine, and 10 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid] buffer) supplemented with 10% interleukin-2 (Human T-Stim; Collaborative Research Inc., Bedford, Mass.), and incubated at 37°C in 5% CO2. H9 cells, a CD4+ human lymphoblastoid cell line,.were provided by R. C. Gallo (National Cancer Institute, Bethesda, Md.) and were maintained in R-10 medium (identical to R-20 mnedium except that it contains only 10% heat-inactivated fetal bovine serum) as previously described (16) .
Virus. The HIV-1 isolate used (HIV-1 14a-PRE) was derived from an HIV-1-seropositive individual before zidovudine (AZT) or other monotherapy and was propagated and titrated in PBMCs as previously described (21) .
Compounds. AZT Table 1 approximate the 50% inhibitory concentrations (IC50s) and were determined by the dose-effect analysis of Chou, Chou, and Talalay (4, 6, 7) as described previously (16, 18, 20, 21 The culture medium was changed twice weekly by resuspending the H9 cells in each well, removing 0.5 ml of the cell suspension, and centrifuging at 300 x g for 10 min. The cell-free supernatant fluid was removed and assayed for p24 antigen. The cell pellets were resuspended in fresh medium containing the drug(s) at the original concentration(s) and placed in new 24-well tissue culture plates. The following drug regimens were evaluated in H9 cells: (i) each agent individually, (ii) AZT plus ddl continuously, (iii) ddC plus IFN continuously, (iv) AZT alternating with ddl, (v) ddC alternating with IFN, (vi) AZT plus ddl alternating with ddC plus IFN, (vii) AZT plus ddl plus ddC, (viii) AZT plus ddl plus IFN, (ix) AZT plus ddC plus IFN, and (x) AZT plus ddl plus ddC plus IFN.
In experiments 4 to 7, uninfected 3-day phytohemagglutininstimulated PBMCs (1.5 x 106 cells) were suspended in a 1.5-ml final volume of R-20 medium supplemented with 10% interleukin-2 in 24-well tissue culture plates. The culture medium was changed twice weekly such that cells were resuspended and 0.95 ml was removed and replaced with 1 ml of fresh medium containing the drug(s) at the original concentration(s). Every second feed day, 106 new 3-day phytohemagglutinin-stimulated PBMCs suspended in 1 ml of fresh medium containing the drug(s) at the original concentration(s) were added. At the times of medium changes, cell-free supernatant fluids were harvested for HIV-1 p24 antigen production. Drug combinations that were directed against a single target (group A) or against multiple targets (group B) were employed. The following combination drug regimens were evaluated in PBMCs: (i) AZT plus PFA plus ddl plus NEV (group A), (ii) AZT plus IFN plus ddl plus Ro31 (group B), (iii) AZT plus PFA alternating with ddl plus NEV, (iv) AZT plus IFN alternating with ddl plus Ro31, (v) all possible three-drug combinations within group A drugs, (vi) all possible three-drug combinations within group B drugs, and (vii) two-drug combinations, including AZT plus PFA, AZT plus ddl, AZT plus NEV, AZT plus IFN, AZT plus Ro3l, ddI plus NEV, ddl plus PFA, ddl plus IFN, ddl plus Ro31, and PFA plus NEV. Single-drug regimens of each individual agent in groups A and B were also tested.
In all experiments, uninfected drug-treated toxicity controls were maintained at the highest concentrations of each agent studied. Cell proliferation and viability were assessed by the trypan blue dye exclusion method (36) .
RESULTS
In H9 cells, there was progressively greater inhibition of HIV-1 replication with increasing number of agents used, such that four drugs were more effective than three drugs, which were more effective than two drugs, which were more effective than single-drug therapy. Figure 1 illustrates the delay in breakthrough of HIV-1 replication (defined as the reproducible emergence of detectable virus in the presence of drug [18, 33] ) and in the time to peak p24 antigen production as more drugs were added to the antiviral regimen in vitro. Viral There was no evidence of drug toxicity to the cells in any of the regimens used as measured by cell proliferation and viability.
In PBMC cultures, four-drug combinations of group A (single-target combination therapy) and group B (multipletarget therapy) drugs at IC99s, IC95s, and IC90s were equally effective in suppressing viral replication in vitro and were able to eliminate detectable HIV-1 from the cultures as evidenced by undetectable p24 levels by day 21 ( Fig. 2A and C) (Fig. 3) . The three-( group A and group B drugs that did r unable to eliminate HIV-1 from the cu At IC99s, two-drug regimens of AZ1 ddl, AZT plus Ro3l, AZT plus NEV, a also able to inhibit viral replication suffi in PBMC cultures (data not shown concentrations, no two-drug combination was able to eliminate HIV-1 from cultures. Even at the highest concentrations used, no single agent was able to eliminate HIV-1 from PBMC cultures. In all cultures in which drug combinations were able to eliminate detectable p24 antigen, PCR assays for proviral DNA were negative. There was no evidence of drug toxicity to the PBMCs in any of the regimens used as measured by cell proliferation and viability.
The IC50s for breakthrough viruses following passage of virus in the presence of simultaneous or alternating drug regimens were equivalent to the IC50s for the infected control (data not shown).
DISCUSSION
Our results, similar to those published previously (8, 10, 13, 16, 18, 20, 21) , suggest that multidrug regimens are more effective in inhibiting viral replication in vitro than single-agent regimens and that this effect increases with the number of drugs used. In this study, we noted that if the drug concentra-________________ !tions were sufficiently high, then two-, three-, and four-drug 30 0 50
regimens were similarly effective in inhibiting HIV-1 replication. Only when the drug concentrations were lowered were differences between two-, three-, and four-drug regimens Infection noted. This pattern was maintained whether combinations of n production in acutely agents acting at the same target site (group A) or at different ree-drug combinations of target sites (group B) were used. )mpared with that of an One cannot necessarily assume that the greater viral suply (no cells) suspended in pression seen with increasing number of agents used is a result the second-highest conof synergistic interactions among the drugs. Because the study believed not to be feasible by any currently available methods of analysis. However, by using the doubling time of replication and the duration of incubation (for the positive log unit of viral growth) and by using a simplified mass action law such as the days (data not shown).
fractional product method (for the negative log unit in inhibi-A and group B drugs at tion) (2, 5, 7, 35) , the net log unit may be used to approximate inate HIV-1 from the the inhibitory outcomes. Such a calculation suggests that some of the observed complete suppression by multiple drugs is not ups A and B were less unexpected. The present studies are the first attempts to ion in vitro than were explore these practical issues experimentally under defined in Fig. 2B and D, only conditions. *e able to block HIV-1
Clinical trials comparing single-drug therapy with combinar a variable length of tion therapy have suggested that during advanced infection, V-1 p24 antigen levels combinations are more effective than single drugs in suppress-)n.
ing p24 antigen levels and maintaining increases in CD4 cell mens of group A drugs counts (17, 26, 28 (25, 30, 33) . The potential advantage of this strategy is that it may reduce dose-limiting or cumulative toxicity by allowing any short-term toxicity of one drug to resolve during the administration of the other. In this study, no toxicity to the cells in culture was noted whether drugs were given simultaneously or on an alternating basis. This may not necessarily reflect all toxicities observed in vivo, and clinical studies will be necessary to determine whether alternating regimens will be less toxic than simultaneous drug regimens. One study has suggested that alternating drug therapy with ddC and AZT may result in reduced hematologic toxicity compared with continuous zidovudine therapy alone, while maintaining similar efficacy (30) .
Our results suggest that although alternating drug regimens are effective, they are no more effective than the single or combination agents given continuously and are less effective than administering all drugs in the regimen simultaneously. These results are expected from calculations using the medianeffect principle (6) . The alternating regimens permit more replication of HIV-1 at the same concentrations of each drug. Another study, evaluating alternating AZT with ddC compared with AZT therapy alone in vitro, suggested that the alternating regimen prolonged the inhibition of HIV-1 in culture compared with monotherapy with AZT alone (33) . No comparison with simultaneous administration of both agents was made in that study. One clinical trial comparing alternating versus continuous ddl and AZT therapy has suggested that continuous concomitant therapy may be better than alternating therapy (37) , which is consistent with our results in vitro. In that clinical study, CD4 cell counts reached higher levels and were more sustained in the continuous regimen than in the alternating regimen. Toxicities in the two groups were equivalent.
The IC50s for breakthrough viruses following passage of virus in the presence of simultaneous or alternating drug regimens were similar to the IC50s of the infected control passaged under the same conditions. This suggests that the breakthrough viruses remained phenotypically susceptible to the drugs in the regimens. Smith et al. have also reported that only drug-susceptible virus was detected following breakthrough of AZT treatment in vitro (31) . Studies that have reported the development of drug resistance in vitro and in vivo have shown that the IC50 for the resistant virus is 4 to 100 times greater than that for the corresponding susceptible viral isolate (11, 14, (22) (23) (24) 34 We thank Joan C. Kaplan for critically reviewing the manuscript.
